- Our Work
- Get Involved
A Multicenter Phase II/II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of VPM1002 in the Prevention of Tuberculosis (TB) Recurrence in Pulmonary TB Patients After Successful TB Treatment in India
Dr. Vidya Mave is leading this clinical trial evaluating the safety and efficacy of a new recombinant BCG vaccine, VPM1002, in preventing TB recurrence among former pulmonary TB patients who have successfully completed first line anti-TB treatment (ATT) and were declared cured. The RePORT India Consortium is participating in this effort.